Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis
Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).
2 findings from 1 review
HR 0.08 [0.02, 0.32]
256 participants
Moderate
HR 0.26 [0.04, 1.69]
137 participants
Very low
Natalizumab · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).
2 findings from 1 review
HR 1 [0.2, 5]
153 participants
Very low
HR 0.24 [0.06, 1]
170 participants
Low
Interferon beta or glatiramer acetate · relapsing multiple sclerosis
Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).
2 findings from 1 review
OR 1.71 [1.11, 2.62]
5477 participants
Moderate
HR 0.14 [0.05, 0.39]
335 participants
Moderate
Ocrelizumab · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes ocrelizumab compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
OR 0.02 [0, 0.4]
472 participants
Very low
Dimethyl fumarate · relapsing multiple sclerosis
Rituximab as 'first choice' showed no clear difference in dimethyl fumarate compared with other disease‐modifying treatments (low certainty).
1 finding from 1 review
HR 0.29 [0.08, 1]
206 participants
Low
Adverse effect: any adverse effects · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes adverse effect: any adverse effects compared with other treatments (very low certainty).
1 finding from 1 review
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes tardive dyskinesia: Not improved to a clinically important extent compared with other treatments (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Intervention not reported
The ability of OWSC, when seen to reach the colon on · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
The rate of resolution of MBO with medical management only in patients receiving OWSC compared with those not receiving it (therapeutic). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Gastrointestinal adverse effects (increased abdominal pain, nausea, vomiting). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
Extra‐abdominal complications (aspiration pneumonia, hypersensitivity reactions). · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Intervention not reported
Length of hospital stay. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time from administration of OWSC to resolution of MBO. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Survival time from onset of inoperable MBO until death. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number with incontinence not improved (women's observations) ‐ Oestrogen vs PPA · patients with urinary incontinence in post‐menopausal women
Oestrogen showed no clear difference in number with incontinence not improved (women's observations) ‐… compared with other treatments (moderate certainty).
1 finding from 1 review
Adverse effects ‐ oestrogen vs PPA · patients with urinary incontinence in post‐menopausal women
1 finding from 1 review